<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The vaginal contraceptive ring is a hormonal contraceptive that releases <z:chebi fb="0" ids="50777">etonogestrel</z:chebi> and <z:chebi fb="0" ids="4903">ethinyl estradiol</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Cerebral venous sinus <z:mp ids='MP_0005048'>thrombosis</z:mp> (CVST) is a rare but serious complication of hormonal contraceptive use </plain></SENT>
<SENT sid="2" pm="."><plain>CASE: We present a case of CVST in a 33-year-old nulligravid woman who was using a vaginal contraceptive ring </plain></SENT>
<SENT sid="3" pm="."><plain>At the time of presentation, she had been using the ring for 18 months, having previously used oral contraceptives for 13 years </plain></SENT>
<SENT sid="4" pm="."><plain>She had no additional risk factors for <z:mp ids='MP_0005048'>thrombosis</z:mp> apart from cigarette smoking </plain></SENT>
<SENT sid="5" pm="."><plain>Despite vigorous management, the patient died from the effects of the CVST </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: The serious adverse effects of the vaginal contraceptive ring are not well known, although <z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo>, <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo>, and aortic <z:mp ids='MP_0005048'>thrombosis</z:mp> in association with use of the ring have been reported to Health Canada </plain></SENT>
<SENT sid="7" pm="."><plain>Continuing post-market surveillance of thrombotic risk in users of the vaginal contraceptive ring is critical </plain></SENT>
</text></document>